24
Feb
To treat kidney cancer in India, Glenmark Pharmaceuticals launched SUTIB (the generic version of Sunitinib oral capsules). Sunitinib is also approved by the US Food and Drug Administration (US FDA). Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumours and advanced renal cell carcinoma. It is also approved for patients with a certain type of Pancreatic Neuroendocrine Tumours. For over a decade, Sunitinib has been well recognized as one of the ‘gold-standard’ of care in cases of fast-spreading (metastatic) renal…
